Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, Scott; Villegas, A.; Daniel, Davey B.; Vicente, David; Murakami, Shuji; Hui, Rina; Kurata, Takeshi; Chiappori, Alberto; Lee, Ki Hyeong; Wit, Maike de; Cho, Byoung Chul; Bourhaba, Maryam; Quantin, Xavier; Tokito, Takaaki; Mekhail, Tarek; Planchard, David; Kim, Young‐Chul; Karapetis, Christos S.; Hiret, Sandrine; Ostoros, Gyula; Kubota, Keiichi; Gray, Jhanelle E.; Paz‐Ares, Luis; Castro, Javier de; Faivre-Finn, Corinne; Reck, Martin; Vansteenkiste, Johan; Spigel, David R.; Wadsworth, Catherine; Melillo, Giovanni; Taboada, Maria; Dennis, Phillip A.; Özgüroǧlu, Mustafa

doi:10.1056/nejmoa1809697

Cited by 2,269 publications

(2,037 citation statements)

References 20 publications

Supporting

Mentioning

1,863

Contrasting

Unclassified

Order By: Relevance

“…The recommendation is based on a new meta-analysis showing improved progression-free survival with this approach 29. There is evidence that immunotherapy after chemoradiotherapy is beneficial 30. Management of localised small cell lung carcinoma is with chemoradiotherapy31; prophylactic cranial irradiation reduces brain metastases and improves survival.…”

Section: What Are the Latest Management Options?mentioning

confidence: 99%

Lung cancer

Neal

Sun

Emery

et al. 2019

BMJ

View full text Add to dashboard Cite

Section: What Are the Latest Management Options?mentioning

confidence: 99%

Lung cancer

Neal

Sun

Emery

et al. 2019

BMJ

View full text Add to dashboard Cite

“…PD‐1/PD‐L1 antibodies, as the so‐called immune‐checkpoint inhibitors, exert an antitumor effect by reversing immune suppression and have demonstrated survival benefits in patients with NSCLC in clinical trials in both first‐ and second‐line settings . However, most participants in clinical trials of immune‐checkpoint inhibitors have come from western countries, with Asian/East Asian patients accounting for only 3%–25.2% of the study populations in clinical trials of PD‐1/PD‐L1 inhibitors for NSCLC . Few studies have thus reported on the efficacy of immunotherapy and the related characteristics in Asian patients …”

Section: Introductionmentioning

confidence: 99%

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

Qian

Nie

Lü

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

This study aimed to compare the differences in characteristics and prognoses between Asian and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC). We studied 390 patients who received atezolizumab as part of the POPLAR or OAK trial, and analyzed the differences in baseline characteristics, outcomes and genetic mutations in blood samples between Asian and white patients. Overall survival (OS) was longer in Asian compared to white patients (median OS: 18.7 vs. 11.1 months; p = 0.005). Race was identified as an independent prognostic factor for OS (Asian vs. white: hazard ratio 0.647, 95% confidence interval 0.447–0.936, p = 0.021), together with performance status, histology, baseline sum of the longest tumor diameters (BLSLD) and number of metastatic sites. The two groups also differed in terms of characteristics including smoking history, BLSLD, epidermal growth factor receptor (EGFR) mutation frequency, programmed death‐ligand 1 expression and blood‐based tumor‐mutation burden. Blood mutations of STK11, EGFR, KEAP1, POLE, GRM3, ATM and STAG2 were associated with treatment response, and TP53, KEAP1, APC, RB1, CREBBP, EPHA5 and STAG2 mutations were associated with OS. The blood‐based mutation profiles differentiated between Asian and white patients, especially in relation to EGFR (23.8 vs. 8.5%), TP53 (30.2 vs. 46.9%) and STK11 (1.6 vs. 12.3%) mutations (all p < 0.05). The different clinicopathological features and mutation profiles in Asian and white patients may explain the superior outcome following atezolizumab treatment in Asian patients with NSCLC. The results of this study have important implications for further studies on racial disparities in relation to immunotherapy.

show abstract

“…The PACIFIC trial tested the efficacy of up to 12 months of durvalumab treatment after curative CCRT in patients with inoperable NSCLC . Compared with placebo, durvalumab showed strongly significant OS benefit, with acceptable toxicity.…”

Section: Concurrent Radiation With Anti‐pd1/pd‐l1 Therapy For Hnsccmentioning

confidence: 99%

Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions

Kao

Lou

2019

Head & Neck

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) can reinvigorate T cells and activate the immune system to eliminate cancer cells. Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis. The roles of ICIs for HNSCC treatments are emerging. Method We reviewed the study results of Programmed‐Death 1 (PD‐1) and PD‐ligand‐1 (PD‐L1) monoclonal antibodies for HNSCC. The ongoing trials of anti‐PD‐1 and anti‐PD‐L1 were also reviewed. Results Nivolumab showed a significant overall survival benefit in platinum‐refractory HNSCC patients. For platinum‐sensitive or first‐line patients, pembrolizumab monotherapy (patients with PD‐L1 Combined Positive Score ≥ 20) or pembrolizumab‐platinum‐fluorouracil improved overall survival vs the EXTREME (cetuximab‐platinum‐fluorouracil). Many HNSCC studies have combined anti‐PD1/PD‐L1 therapy with various anticancer agents or radiotherapy to improve treatment efficacy. Conclusion ICIs demonstrate their efficacies for R/M HNSCC patients. The incorporation of ICIs showed a great impact on the treatment landscape of HNSCC.

show abstract

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Cited by 2,269 publications

References 20 publications

Lung cancer

Lung cancer

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions

Contact Info

Product

Resources

About